Roche’s Sefaxersen reduces proteinuria 43.1% versus placebo in Phase III IgA nephropathy trial

Roche reported that sefaxersen reduced proteinuria by 43.1% versus placebo in a Phase III trial in adults with IgA nephropathy. The treatment was well tolerated, with no new safety signals, and the trial will continue to assess kidney function over two years.